CAR T cells

Phase 3Cell therapy

CAR T cells is one of 195 small molecule programs targeting Malignant Pleural Mesothelioma (MPM). It is currently in Phase 3.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Pleural Mesothelioma (MPM)Active, not recruiting

T CellUnknown status

LymphomaRecruiting

Gastric CancerRecruiting

Multiple MyelomaNot yet recruiting

Immune ThrombocytopeniaRecruiting

Hematological MalignanciesUnknown status

T CellsUnknown status

Immune FunctionRecruiting

Malignant Pleural Mesothelioma (MPM)Phase 1

Active, not recruiting

T CellPreclinical

Unknown status

LymphomaPhase 2

Recruiting

Gastric CancerPhase 3

Recruiting

Multiple MyelomaPhase 2

Not yet recruiting

Immune ThrombocytopeniaPhase 2

Recruiting

Hematological MalignanciesPhase 2

Unknown status

T CellsPhase 2

Unknown status

Immune FunctionPhase 1

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

CAR T cells

CChongqing Precision Biotech Co., Ltd

Phase 3

7 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Lymphoma

NCT06822868

Phase 1Active, not recruiting

Malignant Pleural Mesothelioma (MPM)

NCT04577326

Q4 2026

Phase 1Recruiting

Hematological Malignancies

NCT04532203

Phase 1Recruiting

Lymphoma

NCT07053670

Phase 1Not yet recruiting

Lymphoma

NCT07032324

Q2 2027

Phase 3Recruiting

Gastric Cancer

NCT07103668

Clinical

Trials by Indication[1]

Lymphoma7 trials

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·KKai Hu·Phase 1·NCT06822868·24 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Recruiting·TTongji Hospital·Phase 1·NCT07053670·27 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Recruiting·AAibin Liang，MD，Ph.D.·Phase 1·NCT06734871·24 enrolled

Show 4 more trials

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Recruiting·NNational University of Malaysia·Phase 2·NCT06698484·20 enrolled

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT05420493·54 enrolled

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting·BBenjamin Tomlinson·Phase 1·NCT03434769·31 enrolled

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

Not yet recruiting·QQian Wenbin·Phase 1·NCT07032324·27 enrolled

Hematological Malignancies3 trials

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Available·IInstitute of Hematology & Blood Diseases Hospital, China··NCT04008524

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Recruiting·ZZhejiang University·Phase 1·NCT04532203·72 enrolled

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Unknown status·ZZhejiang University·Phase 1/2·NCT04790747·50 enrolled

T Cells2 trials

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT05779917·30 enrolled

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Unknown status·TThe First Affiliated Hospital of Guangdong Pharmaceutical University·Phase 1/2·NCT03525782·60 enrolled

Multiple Myeloma2 trials

Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT06429150·20 enrolled

Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03271632·20 enrolled

Advanced Solid Tumors1 trial

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

Unknown status·SShanghai Cell Therapy Group Co.,Ltd·Phase 1·NCT05089266·30 enrolled

10 more indications

HIV-1 infection1 trial

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection

Unknown status·—·Phase 1·NCT04863066·8 enrolled

Immune Thrombocytopenia1 trial

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Recruiting·—·Phase 1/2·NCT06352281·10 enrolled

B-cell Malignancies1 trial

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Unknown status·HHenan Cancer Hospital·Phase 1·NCT03881774·20 enrolled

T Cell1 trial

Universal CAR-γδT Cell Injection in the AML Patients

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT05388305·30 enrolled

Refractory1 trial

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Completed·UUppsala University·Phase 2·NCT03068416·24 enrolled

Treatment1 trial

Donor-derived CAR-T Cells in the Treatment of AML Patients

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT04766840·9 enrolled

Acute Lymphoblastic Leukemia1 trial

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Unknown status·—·Phase 1·NCT02186860·5 enrolled

Gastric Cancer1 trial

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 3·NCT07103668·150 enrolled

Immune Function1 trial

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Recruiting·GGuangzhou 8th People's Hospital·Phase 1·NCT03240328·40 enrolled

Malignant Pleural Mesothelioma (MPM)1 trial

A Single-Arm, Open-Label, Phase I Trial to Assess the Safety of Genetically Engineered Autologous T Cells Targeting the Cell Surface Antigen Mesothelin With Cell-Intrinsic Checkpoint Inhibition in Patients With Mesothelioma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04577326·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: CChongqing Precision Biotech Co., Ltd

CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Trials by Indication[1]

Lymphoma7 trials

Hematological Malignancies3 trials

T Cells2 trials

Multiple Myeloma2 trials

Advanced Solid Tumors1 trial

HIV-1 infection1 trial

Immune Thrombocytopenia1 trial

B-cell Malignancies1 trial

T Cell1 trial

Refractory1 trial

Treatment1 trial

Acute Lymphoblastic Leukemia1 trial

Gastric Cancer1 trial

Immune Function1 trial

Malignant Pleural Mesothelioma (MPM)1 trial

References

Drug Info

Quick Facts

Related News